Recent studies demonstrated that SARS-CoV-2 specific CD4+ T and CD8+ T cells in COVID-19 convalescent individuals had strong ex vivo proliferation capacities, implying that the induction of T lymphocyte proliferation should be an important immunological parameter to evaluate an effective COVID-19 vaccine candidate. This evidence concerns the gene CD4 and COVID-19.